Search Results for "BIAL Pharmaceuticals"

01:24 EST 29th January 2015 | BioPortfolio

Original Source: Bial and Eisai

Founded in 1924, Bial is an international pharmaceutical group with products available in over 30 countries throughout four continents. BIAL is the largest Portuguese pharmaceutical company and is based in S. Mamede do Coronado, Portugal.

Matching Channels

None

Matching News

Bial - Portela & Ca, S.A. - Product Pipeline Review - 2014

Bial - Portela & Ca, S.A. - Product Pipeline Review - 2014 Summary Global Markets Direct’s, ‘Bial - Portela & Ca, S.A. - Product Pipeline Review - 2014’, provides an overview of the Bial...

Bial-Portela, moksha8 deal

Bial - Portela & Ca, S.A. - Product Pipeline Review - 2014

Recently added to the BioPortfolio report store, Bial - Portela & Ca, S.A. - Product Pipeline Review - 2014 is a new report from Global Markets Direct published on 2014-07-21. This 36-page report...

Former Roche CEO joins BIAL board

Franz Humer to advise Portuguese pharma company

Seizures Global Clinical Trials Review, H2, 2014

Recently added to the BioPortfolio report store, Seizures Global Clinical Trials Review, H2, 2014 is a new report from GlobalData published on 2014-07-27. This 112-page report is available in PDF fro...

Eisai files Fycompa for wider epilepsy use

Eisai is looking to extend the use of its epilepsy treatment Fycompa into use as adjunctive treatment of serious seizures uncontrolled by existing treatment.Eisai has just submitted the drug...

Sunovion Pharmaceuticals Inc. Announces FDA Acceptance for Review of Supplemental New Drug Application for the Use of Aptiom® (eslicarbazepine acetate) as Monotherapy Treatment for Partial-Onset Seizures

Sunovion Pharmaceuticals Inc. (Sunovion) announced today the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for the use...

Sunovion Pharmaceuticals Inc. Submits Supplemental New Drug Application Seeking Approval for the Use of Aptiom® (eslicarbazepine acetate) as Monotherapy Treatment for Partial-Onset Seizures

Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking ap...

Matching PubMed Articles

None

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement